Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Study:

A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Rationale:

n/a

Purpose:

This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon ß-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Multiple Sclerosis Drug: Fingolimod 1.25 mg
Drug: Fingolimod 0.5 mg
Drug: Interferon ß-1a 30 µg
Phase 3

Verified by Novartis July, 2012

Sponsored by: Novartis
Information provided by: Novartis
ClinicalTrials.gov identifier: NCT00340834

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Novartis Pharmaceuticals., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site